Prognostic impact of genetic abnormalities in patients with B-ALL after CAR19/22 T-cell cocktail therapy. PFS (A) and OS (B), according to risk-stratified genetic subtypes. In the patients with Ph⁺, the median PFS was 15.4 months (95% CI, 3.4-NR), and the median OS was 31.0 months (95% CI, 31.0-NR). In the patients with hypodiploidy, the median PFS was NR (95% CI, 3.8-NR), and the median OS was 31.0 months (95% CI, 3.8-31.0). In the patients with T315I mutation in ABL kinase, the median PFS and median OS were NR. In the patients with del(17p) or the TP53 mutation, the median PFS was 14.0 months (95% CI, 4.9-NR), and the median OS was NR. In the patients with MLL rearrangements, the median PFS and median OS were NR. In the patients with Ph-like B-ALL, the median PFS was 6.2 months (95% CI, 2.0-NR), and the median OS was 8.5 months (95% CI, 5.9-NR). In the patients with RAS pathway mutations, including mutations in genes NRAS, KRAS, and PTPN11, the median PFS was 2.0 months (95% CI, 1.0-16.2), and the median OS was 4.9 months (95% CI, 1.0-17.2). In the patients without the above-mentioned aberrations (W/O), the median PFS was 14.9 months (95% CI, 5.8-NR), and the median OS was NR (95% CI, 7.3-NR). PFS (C) and OS (D), according to Ph status. In the patients with Ph⁺, the median PFS was 15.4 months (95% CI, 3.4-NR), and the median OS was 31.0 months (95% CI, 31.0-NR). In the patients with Ph⁻, the median PFS was 12.8 months (95% CI, 5.8-NR), and the median OS was 16.7 months (95% CI, 8.9-NR).